31results about How to "Strong immune response" patented technology

The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.

The invention relates to a novel coronavirus recombinant chimeric antigen, a related product thereof, a preparation method and application of the novel coronavirus recombinant chimeric antigen in preparation of a novel coronavirus vaccine. The recombinant chimeric antigen is a recombinant new coronavirus Omicron variant RBD trimer antigen, various types of vaccines based on the recombinant chimeric antigen can induce strong immune response aiming at various subtype variants (including BA.1, BA.2, BA.5, XBB, EG.5, BA.2. 86, JN.1, KP.2 and the like) of the new coronavirus Omicron, and particularly, compared with a protein vaccine of the recombinant chimeric antigen, the recombinant chimeric antigen can induce strong immune response. The mRNA vaccine based on the recombinant chimeric antigen can induce an organism to generate obviously higher RBD specific binding antibody level and neutralizing antibody level, so that the mRNA vaccine can be used as a candidate of a new generation of new coronavirus vaccines, and has potential clinical application value and prospect.

The invention relates to a nanoparticle vaccine for mucosal immunity and a preparation method and application thereof. The nanoparticle is of a core-shell structure, the core is a compound with a hydrophobic group, the shell is maltodextrin, and the surface of the shell is loaded with a conjugate of an antigen protein coupled cationic polymer and an adjuvant. The prepared nano-particle vaccine can be used for mucosal immunity, co-delivery of a vaccine adjuvant and high-molecular-weight antigen protein is achieved, mucosal immune response of a body can be remarkably enhanced, meanwhile, strong systemic humoral immunity and cellular immune response can be induced, and the nano-particle vaccine is uniform in particle size and good in dispersity.

This invention belongs to the field of immunology and relates to a single-domain antibody against TSLP and its uses. The single-domain antibody is composed of heavy chains, including heavy chain CDR1 shown in any one of SEQ ID NO:42-SEQ ID NO:48 or SEQ ID NO:73, heavy chain CDR2 shown in any one of SEQ ID NO:49-SEQ ID NO:50, and heavy chain CDR3 shown in any one of SEQ ID NO:51-SEQ ID NO:61 or SEQ ID NO:74-SEQ ID NO:75. Compared with the prior art, the beneficial effects of this invention are: this invention uses bioengineering technology to screen for single-domain antibodies specifically targeting TSLP, and the antibody affinity is good.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

An anti-MASP2 antibody, an antigen-binding fragment thereof and the medical use thereof. Specifically, provided are an anti-MASP2 antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof, a method for treating diseases such as IgA nephropathy and a related pharmaceutical use.

The invention discloses a preparation method and application of an anti-aging vaccine, and relates to the technical field of medical treatment. Comprising the following steps: 1, synthesizing a polypeptide with a specific sequence; 2, coupling the polypeptide with a carrier protein; adding an immunologic adjuvant, and fully and uniformly mixing at room temperature to obtain a polypeptide solution; 3, freeze-drying the polypeptide solution to obtain a freeze-dried pure product; and dissolving the freeze-dried pure product in ultrapure water, filling into a sterile EP tube, and storing at-20 DEG C to obtain the anti-aging polypeptide vaccine. The anti-aging polypeptide vaccine has the beneficial effects that the polypeptide sequences (A: RRGDGRWKD, B: RSQHLRFPDR, and C: TGRRLFCYS) are designed to create the polypeptide vaccine, and the polypeptide vaccine can effectively act on cells with high expression of GPNMB, so that the anti-aging effect is achieved.

The present invention relates to a synthetic biology self-assembly vaccine production system and a method for producing a vaccine, wherein the system comprises a base sequence component capable of expressing an antigen, and the system is a sequence capable of enriching in host tissues and organs, expressing the antigen on the surface of a vesicle, and self-assembling into a vesicle complex, wherein the vesicle complex can induce an immune response. In the present invention, the base sequence component has the advantages of low production cost, stable physical and chemical properties, efficient antigen assembly and secretion process, fast response to pathogen mutation, strong immune response induced, high safety and protection, etc., providing a new type of vaccine.

The application belongs to the field of immunology and relates to an anti-LAG3 single-domain antibody and use thereof.The single-domain antibody is composed of a heavy chain, the heavy chain comprising heavy chain CDR1 shown in any one of SEQ ID NO:22-SEQ ID NO:26, heavy chain CDR2 shown in any one of SEQ ID NO:27-SEQ ID NO:29, and heavy chain CDR3 shown in any one of SEQ ID NO:30-SEQ ID NO:34.The beneficial effect of the application relative to the prior art is that the application uses biological genetic engineering technology to screen out a single-domain antibody specific to LAG3, and the antibody has good affinity.

The present invention relates to the use of beta-glucan as a C-type lectin (CLEC) polysaccharide adjuvant for B-cell or T-cell epitope polypeptides.

The present invention discloses a method for constructing a DNA vaccine for co-expressing Marek's disease virus glycoprotein gC and gD. It belongs to the technical field of DNA molecular vaccines. It includes: Marek's disease virus glycoprotein gC and gD genes, IL-18 gene, self-cleavage polypeptides P2A and T2A, and eukaryotic expression vectors, and provides a construction method and application. The operation method of the present invention is simple, the preparation time is short, and large-scale production can be carried out; the homologous sequence between the vector and the target gene is recombined by a recombinase, and the PCR cloned product can be directly used for recombination, and the three target genes are expressed separately; it is conducive to the processing and presentation of the product of the antigen gene in the body; it is safe and reliable, and easy to store and transport. Animal experiments show that the weight of three yellow chickens immunized with DNA vaccines increases normally, no side effects occur, and the immunized chickens produce obvious humoral immunity and cellular immune responses.

The invention relates to a conjugate of a dual agonist and a carbohydrate antigen, the conjugate contains the dual agonist and the carbohydrate antigen, the dual agonist is an iNKT cell agonist and a mincle receptor agonist, the iNKT cell agonist is an alpha-galactosylceramide analogue, and the mincle receptor agonist is a trehalose derivative; the structural general formula of the conjugate is as shown in formula (I): # imgabs0 # X is a carbohydrate antigen, and Y is a linker. The vaccine prepared from the conjugate can activate iNKT cells and mincle receptors at the same time, induce generation of high-titer IgG antibodies and effectively improve the immunogenicity of carbohydrate antigens, and has a good anti-tumor application prospect.

The invention discloses an oral drug delivery system for targeting mesenteric lymph nodes, a novel LNP oral delivery carrier for simulating release of chyloparticle drugs is prepared, and a way and a method for targeting intestinal chylolymphatic vessels are explored by performing targeted group modification on a carrier material. Compared with the prior art, the intestinal epithelial barrier penetrating capacity of the nano-drug can be remarkably improved, the targeting property of the nano-drug is enhanced, and the oral drug has remarkable advantages in the aspects of improving vaccine stability, enhancing immune response and reducing side effects through wrapping of the calcium alginate hydrogel.

The application belongs to the field of immunology and relates to a single-domain antibody against IL-17A and use thereof.The single-domain antibody is composed of a heavy chain, and the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3.The amino acid sequences of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 are one of (2)-(4) or (6)-(8).Compared with the prior art, the application has the beneficial effect that the single-domain antibody specific to IL-17A is screened by using biological genetic engineering technology, the antibody has good affinity, can block the release of cytokines by specific cells, has good binding activity through prokaryotic expression and eukaryotic expression, and has certain drugability.

The application provides an active polypeptide and application in prevention and / or treatment of HPV, and belongs to the technical field of biological medicine. The application provides a polypeptide with prevention and / or treatment activity, and the sequence of the polypeptide comprises SEQ ID No. 1. The polypeptide can directly serve as a medicine to effectively activate immunity, inhibit and eliminate human papilloma virus. The polypeptide can be used for injection alone as a medicine. The polypeptide can also induce single nucleated cells (PBMC) in vitro, culture CTL cells with specific killing of HPV, and through reinfusion of the CTL cells into a patient, directly kill tumors or stimulate immune response of the body, effectively kill HPV, make HPV in the patient turn from positive to negative, and finally achieve the effect of treatment. The polypeptide can also serve as a medicine for prevention of HPV, effectively stimulate strong immune response, and make the body produce a large number of immune cells to achieve the effect of protection and prevention.

The invention relates to rOmpW, in particular to an rOmpW nano vaccine with human neutrophile granulocyte membrane coated PLGA modified by DC targeting peptide as well as a preparation method and application of the rOmpW nano vaccine. The core of the nano delivery system is composed of PLGA nano particles, a layer of human neutrophile cell membrane is wrapped outside the PLGA nano particles, and DCpep is modified on the outer surface of the human neutrophile cell membrane. According to the invention, the DCpep modified human neutrophile granulocyte membrane coated PLGA nano-carrier is used for loading the acinetobacter baumannii epitope vaccine rOmpW for the first time, so that the degradation of polypeptide is prevented, and meanwhile, the immune efficacy is improved.

Provided are an anti-CD40 antibody, an antigen-binding fragment and a medical use thereof, as well as a pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof, and a method for treating and preventing disease, in particular a method for treating autoimmune disease.

The invention relates to a CD33 binding molecule and application thereof. The binding molecule of the CD33 comprises a CDR1, a CDR2 and a CDR3, wherein the CDR1, the CDR2 and the CDR3 are selected from the following amino acid sequences: the CDR1 shown as any one of SEQ ID NO: 24-26; cDR2 as shown in any one of SEQ ID NO: 27-29; the CDR3 is shown as any one of SEQ ID NO: 30-34. According to the invention, the anti-CD33 single-domain antibody specifically combined with CD33 is screened by using a biological gene engineering technology, CDR modification is carried out, and the antibody has good affinity and is used for treating hematological malignant tumors and other CD33 related diseases.

The present invention discloses an antigen delivery carrier that targets dendritic cells, promotes antigen lysosomal escape, and activates the immune system, and its preparation method and application. The present invention provides a carrier for delivering antigens into the body, which is a metal skeleton complex obtained by functionally modifying a metal skeleton material with polyethyleneimine and mannose. The antigen delivery carrier provided by the present invention has uniform particle size, good dispersibility, high biosafety, and a large antigen loading capacity. It exhibits high targeting to dendritic cells, increases the uptake of antigens by dendritic cells, promotes the maturation of dendritic cells, and promotes the cross-presentation of antigens in dendritic cells, and can efficiently activate CD4 + and CD8 + T cells, causing a strong immune response and killing cancer cells. This carrier has a wide range of applications and can be used to encapsulate single or multiple antigens, and has the ability to kill common tumors.

The present invention relates to the field of molecular biology and immunology technology, and specifically discloses an application of a Mycobacterium tuberculosis T cell epitope protein Rv1566c-444. The present invention provides an application of a Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 in the preparation of tuberculosis detection reagents and vaccines; wherein the amino acid sequence of the Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 is shown in SEQ ID NO.4. The Mycobacterium tuberculosis T cell epitope protein Rv1566c-444 of the present invention can reduce false negatives caused by the stimulation of T cells by intrinsic protein antigens of the test kit, thereby improving the detection sensitivity. The cellular immune response is good, and it can be widely used in related fields such as auxiliary diagnosis of tuberculosis, epidemiological monitoring and infection screening, and provides a new idea for the development of new anti-tuberculosis vaccines.

The invention belongs to the field of immunology, and relates to an antigen binding protein combined with CD123 and application of the antigen binding protein. The antigen binding protein bound with CD123 comprises an anti-CD123 single-domain antibody, the anti-CD123 single-domain antibody is composed of heavy chains, and the heavy chains comprise a heavy chain CDR1 as shown in any one of SEQ ID NO: 25 to SEQ ID NO: 30, a heavy chain CDR2 as shown in SEQ ID NO: 31 and a heavy chain CDR3 as shown in any one of SEQ ID NO: 32 to SEQ ID NO: 33. The CD123 single-domain antibody has the beneficial effects that the specific CD123 single-domain antibody is screened by using a biological gene engineering technology, and the affinity of the antibody is relatively good.

The invention relates to a dendrimer-based polypeptide nano vaccine as well as a preparation method and application thereof. The polypeptide nano vaccine is obtained by loading MnO2 nano particles on a functionalized dendrimer and wrapping a polypeptide antigen. After the polypeptide nano vaccine disclosed by the invention is injected into a mouse body through peritumoral injection, MnO2 plays a chemical kinetic treatment role through a Fenton-like reaction, and tumor cells are induced to generate immunogenic cell death, so that dendritic cell maturation is promoted; meanwhile, the polypeptide nano vaccine can activate an immune system and initiate potent immune response by activating a cGAS-STING pathway and being cooperated and combined with presentation of a polypeptide antigen OVA257-264, a new chemical kinetics / immune combined treatment strategy is provided, and the polypeptide nano vaccine has a remarkable inhibition effect on tumor growth and recurrence and has potential application value in the field of biological medicine.

The present invention belongs to the field of biotechnology, and discloses a bivalent subunit vaccine of Streptococcus suis and swine erysipelas, and a preparation method and application thereof. The antigen components of the subunit vaccine are Streptococcus suis AbpB protein, Streptococcus suis AATS protein and swine erysipelas SpaA protein, the amino acid sequence of Streptococcus suis antigen protein AbpB is shown in SEQ ID NO.4, the amino acid sequence of Streptococcus suis antigen protein AATS is shown in SEQ ID NO.5, and the amino acid sequence of swine erysipelas antigen protein SpaA is shown in SEQ ID NO.6. The bivalent subunit vaccine of the present invention has good safety for target animal pigs, and has high immunogenicity, and "one shot for multiple protection" can effectively prevent and treat zoonotic diseases of Streptococcus suis and swine erysipelas.

The invention provides a method for preparing a mineralized collagen material from pig-derived tissues. The prepared bone repair material can be used for bone defect filling repair and spinal fusion surgery. The method comprises the steps of pretreatment, enzymolysis, collagen fibrosis, mineralization, washing, slurry preparation, freeze drying, crosslinking, packaging and sterilization and the like. The obtained material has rapid liquid absorbability and adjustable porosity. The material can be mixed with bone fragments of a patient to form stable paste, components and structures similar to those of surrounding bone tissues are formed after bone defects are filled, and osseointegration is promoted. The pore structure can be adjusted to meet different operation requirements, and the integration effect with bone tissue is improved. The material provided by the invention can stably integrate a bioactive agent while keeping the structural integrity of collagen, does not influence the functions of the bioactive agent, improves the clinical effects of osseointegration and spinal fusion, and has wide application potential.

The present invention discloses a paratuberculosis subunit vaccine and its preparation method and application. The vaccine contains 89AP recombinant antigen, which is a recombinant antigen of Mycobacterium paratuberculosis ( Mycobacterium avium subsp.paratuberculosis , MAP) map3527、 map1609c and p22 The study found that the recombinant antigen 89AP can not only induce strong cellular and humoral immune responses in mice, but also provide good protection against MAP infection, and will not interfere with the quarantine of tuberculosis and paratuberculosis, indicating that 89AP is an ideal subunit candidate vaccine for paratuberculosis, and provides a new technical means for the development of new paratuberculosis vaccines.

The invention provides preparation of a copper salt of an STING agonist MSA-2 and a lipid nanomaterial combined with the copper salt and application of the copper salt and the lipid nanomaterial in tumor treatment. The invention provides two strategies for improving anti-tumor treatment of the MSA-2. Firstly, a compound MSA-2-Cu of copper modified MSA-2 is synthesized in the application, and the method shows that the cytotoxicity of Cu enhances the STING pathway. In the invention, 81 ionizable phospholipid nanoparticles are also synthesized, and the phospholipid nanoparticle 1AP27 (at) STING mRNA can be used for effectively transmitting STIING-mRNA, so that the expression of STING protein is increased. The 1AP27 (at) STING mRNA is combined with MSA-2-Cu, so that the growth of a B16F10 tumor can be remarkably reduced, and the survival rate of a mouse is increased. The treatment of 1AP27 (at) STING mRNA + MSA-2-Cu in the application stimulates a strong immune response by activating a cGAS-STING pathway, the anti-tumor effect of MSA-2 is improved, and a strategy with a wide prospect is provided for enhancing tumor immunotherapy.

One or more data objects defining a plurality of wild-type amino acid sequences are received. A plurality of dimensionality reduction sequences are generated in a dimensionality reduction space from one or more data objects. A plurality of candidate sequences are generated in a dimensionality reduction space using the plurality of dimensionality reduction sequences. One or more data objects defining a viral amino acid sequence are received. A virus sequence in a dimensionality reduced space is received. Each of the candidate sequences and at least one of the dimensionality-reduced viral sequences are provided as inputs to a titer predictor. A candidate score for each candidate sequence is received as an output of the slave titer predictor. At least one candidate sequence is selected from the candidate sequences. And generating at least one new amino acid sequence. Each generated amino acid sequence is suitable for the manufacture of a corresponding vaccine.

The invention discloses a lactobacillus reuteri strain as well as an outer vesicle and application thereof. The lactobacillus reuteri strain is named as C186 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the microbial preservation number of the lactobacillus reuteri strain is CGMCC No.30337, and the preservation date is April 15, 2024. Researches show that the strain has excellent immunoregulation characteristics, acid resistance, cholate resistance and the like, the strain can generate extracellular vesicles with immunological enhancement activity, and the extracellular vesicles can directly activate chicken Hastelloid lymphocytes and tracheal endothelium lymphocytes only by dripping nasal drops to eyes, so that mucosal immune response is remarkably enhanced. When the lactobacillus reuteri strain C186 or the exovesicles thereof are added into feed or medicines, the effects of the feed or the medicines on enhancing the immune response and health care of the body can be improved, and the lactobacillus reuteri strain C186 or the exovesicles thereof is expected to be used as a natural delivery carrier for researching and developing novel oral vaccines and mucous membrane delivery vaccines.

The present invention belongs to the field of monoclonal antibody technology, and specifically discloses a novel coronavirus RBD-specific monoclonal antibody and the application of the novel coronavirus RBD-specific monoclonal antibody. The present invention has important scientific significance and application prospects for the prevention, clinical treatment and development of diagnostic reagents for diseases caused by the novel coronavirus SARS-CoV-2.